HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography

important for initial diagnosis, and that a per-vessel assessment provides additional information to inform patient management. The committee concluded that per-patient level figures were the most reliable and relevant to the diagnosis of coronary artery disease. 4 NHS considerations System impact 4.1 The company's claimed system benefits included reduced costs from fewer inconclusive or inaccurate diagnostic tests and avoidance of unnecessary staff and procedure costs. It claimed that this would lead to more effective use of invasive procedure suites. 4.2 The company confirmed that, with specific reference to the updated NICE guideline on chest pain, the proposed place in the diagnostic pathway for HeartFlow FFR (to inform management following a positive coronary CT CT angiography [CCTA] result) was unchanged. 4.3 Conservative estimates by the NICE resource impact assessment team suggest that by 2021/22, when fully implemented, HeartFlow FFR will potentially be CT used in around 40,000 patients a year. This would equate to national savings of at least Â£9.1 million a year. 4.4 During selection and routing, the committee asked for additional information on compliance with data protection legislation, and the reproducibility of HeartFlow FFR analysis, especially in the face of an increasing workload which CT might be expected to
